Figure 2 (Continued).
Forest plots for meta-analysis of the effects of SGLT2 inhibitors on cardiovascular outcomes in MACEs (A), myocardial infarction (B), ischemic stroke (C), cardiovascular death (D), and all-cause mortality (E) in patients with type 2 diabetes. Summary effects for all drugs were obtained from a fixed-effects meta-analysis.